IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐Cov‐2) with digital drug development

IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐Cov‐2) with digital drug development

Abstract The emergence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) led to multiple drug repurposing clinical trials that have yielded largely uncertain outcomes. To overcome this challenge, we used IDentif.AI, a platform that pairs experimental validation with artificial intellig...

Full description

Bibliographic Details
Main Authors: Agata Blasiak, Jhin Jieh Lim, Shirley Gek Kheng Seah, Theodore Kee, Alexandria Remus, De Hoe Chye, Pui San Wong, Lissa Hooi, Anh T. L. Truong, Nguyen Le, Conrad E. Z. Chan, Rishi Desai, Xianting Ding, Brendon J. Hanson, Edward Kai‐Hua Chow, Dean Ho
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Bioengineering & Translational Medicine
Subjects:
artificial intelligence
combinatory treatment
COVID‐19
digital medicine
drug development
drug interactions
Online Access:https://doi.org/10.1002/btm2.10196

Internet

https://doi.org/10.1002/btm2.10196

Similar Items